CY1107435T1 - Σταθερα υδατικα διαλυματα του παραγοντα διεγερσεως αποικιων κοκκιοκυτταρων μακροφαγων - Google Patents

Σταθερα υδατικα διαλυματα του παραγοντα διεγερσεως αποικιων κοκκιοκυτταρων μακροφαγων

Info

Publication number
CY1107435T1
CY1107435T1 CY20071101016T CY071101016T CY1107435T1 CY 1107435 T1 CY1107435 T1 CY 1107435T1 CY 20071101016 T CY20071101016 T CY 20071101016T CY 071101016 T CY071101016 T CY 071101016T CY 1107435 T1 CY1107435 T1 CY 1107435T1
Authority
CY
Cyprus
Prior art keywords
aqueous solutions
stimulating factor
macrophage colony
solid aqueous
solid
Prior art date
Application number
CY20071101016T
Other languages
English (en)
Inventor
Dean K PETTIT
Claudia M. Jochheim
Original Assignee
Bayer Schering Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Aktiengesellschaft filed Critical Bayer Schering Pharma Aktiengesellschaft
Publication of CY1107435T1 publication Critical patent/CY1107435T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Abstract

H εφεύρεση παρέχει συνθέσεις του GM-CSF στις οποίες έχει προβλεφθεί ένας παράγοντας χηλικοποιήσεως για να σταθεροποιεί τον GM-CSF έναντι της Ν-τερματική αποσυνθέσεως.
CY20071101016T 2001-03-05 2007-07-30 Σταθερα υδατικα διαλυματα του παραγοντα διεγερσεως αποικιων κοκκιοκυτταρων μακροφαγων CY1107435T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/800,016 US20020141970A1 (en) 2001-03-05 2001-03-05 Stable aqueous solutions of granulocyte macrophage colony-stimulating factor
PCT/US2002/006428 WO2002069999A1 (en) 2001-03-05 2002-03-04 Stable aqueous solutions of granulocyte macrophage colony-stimulating factor

Publications (1)

Publication Number Publication Date
CY1107435T1 true CY1107435T1 (el) 2012-01-25

Family

ID=25177307

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071101016T CY1107435T1 (el) 2001-03-05 2007-07-30 Σταθερα υδατικα διαλυματα του παραγοντα διεγερσεως αποικιων κοκκιοκυτταρων μακροφαγων

Country Status (10)

Country Link
US (3) US20020141970A1 (el)
EP (1) EP1372700B1 (el)
JP (2) JP2004536038A (el)
AT (1) ATE362375T1 (el)
CY (1) CY1107435T1 (el)
DE (1) DE60220149T2 (el)
DK (1) DK1372700T3 (el)
ES (1) ES2287296T3 (el)
PT (1) PT1372700E (el)
WO (1) WO2002069999A1 (el)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2217977B1 (es) * 2003-04-29 2006-02-01 Antonio Bru Espino Procedimiento para la preparacion de un medicamento para la terapia antitumoral por intervencion de neutrofilos (terapia de neutrofilos).
US9052289B2 (en) * 2010-12-13 2015-06-09 Schlumberger Technology Corporation Hydrogen sulfide (H2S) detection using functionalized nanoparticles
US9855316B2 (en) * 2011-04-07 2018-01-02 Reponex Pharmaceuticals Aps Granulocyte-macrophage colony stimulating factor for enhancing pulmonary host defense in acute and chronic radiation syndrome, therapeutic radiation intervention and cancer therapy
US20160215033A1 (en) * 2013-09-03 2016-07-28 Sloan-Kettering Institute For Cancer Research Granulocyte Macrophage Colony-Stimulating Factor Compositions
US10105415B2 (en) 2014-07-24 2018-10-23 Reponex Pharmaceuticals A/S Compositions comprising granulocyte-macrophage colony-stimulating factor for the treatment of inflammatory bowel disease
WO2020002650A1 (en) * 2018-06-29 2020-01-02 Targovax Asa A formulation
US20230201307A1 (en) 2020-03-17 2023-06-29 Drugrecure Aps Liquid formulation of gm-csf for inhalation

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5534001A (en) * 1978-08-28 1980-03-10 Noda Sangyo Kagaku Kenkyusho Stabilization of sarcosine oxidase
US4900730A (en) * 1981-01-14 1990-02-13 Toyo Jozo Co., Ltd. Preparation which promotes the absorption of peptides
US4760025A (en) * 1984-05-29 1988-07-26 Genencor, Inc. Modified enzymes and methods for making same
AU588819B2 (en) * 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
EP0276846A3 (en) * 1987-01-29 1989-07-26 Zymogenetics, Inc. Colony-stimulating factor derivatives
DE3726324A1 (de) * 1987-08-07 1989-02-16 Hoechst Ag Cyclopeptide als resorptionsfoerderer bei applikation auf die schleimhaeute
US5104651A (en) * 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
US5182258A (en) * 1989-03-20 1993-01-26 Orbon Corporation Systemic delivery of polypeptides through the eye
US5130418A (en) * 1989-05-02 1992-07-14 California Biotechnology Inc. Method to stabilize basic fibroblast growth factor
US5217954A (en) * 1990-04-04 1993-06-08 Scios Nova Inc. Formulations for stabilizing fibroblast growth factor
AU1372692A (en) * 1991-02-08 1992-09-07 Immunex Corporation Method of inhibiting replication of hiv in macrophages
JPH06500699A (ja) * 1991-04-12 1994-01-27 ザ チルドレンズ ホスピタル オブ フィラデルフィア 新規なエンドペプチダーゼ
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
GB9122820D0 (en) * 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
FR2693907B1 (fr) * 1992-07-23 1994-09-02 Rhone Poulenc Rorer Sa Procédé d'administration de solutions de facteur de stimulation des colonies granulocytaires.
DE4242919A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Verfahren zur Herstellung von lagerstabilen wässrigen pharmazeutischen Zubereitungen von G-CSF
DE4242863A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
US6692766B1 (en) * 1994-06-15 2004-02-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Controlled release oral drug delivery system
US6743779B1 (en) * 1994-11-29 2004-06-01 Imarx Pharmaceutical Corp. Methods for delivering compounds into a cell
US5653987A (en) * 1995-05-16 1997-08-05 Modi; Pankaj Liquid formulations for proteinic pharmaceuticals
US5902785A (en) * 1995-06-06 1999-05-11 Genetics Institute, Inc. Cartilage induction by bone morphogenetic proteins
US6579516B1 (en) * 1995-06-13 2003-06-17 Zahra Mansouri Methods of delivering materials into the skin, and compositions used therein
FR2742756B1 (fr) * 1995-12-22 1998-04-03 Pasteur Merieux Serums Vacc Stabilisants pour vaccins vivants, vaccins les contenant et procedes pour leur preparation
US5770700A (en) * 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
GB9610992D0 (en) * 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
JPH11315096A (ja) * 1997-08-08 1999-11-16 New Food Creation Gijutsu Kenkyu Kumiai タモギタケ由来の抗腫瘍性タンパク質およびその遺伝子
US6261764B1 (en) * 1997-09-22 2001-07-17 Chiron Corporation Buffers for stabilizing antigens
ATE373957T1 (de) * 1997-10-09 2007-10-15 Univ Emory Verfahren und vorrichtung zur transdermalen verabreichung von lithium
US6017545A (en) * 1998-02-10 2000-01-25 Modi; Pankaj Mixed micellar delivery system and method of preparation
US7070799B1 (en) * 1998-02-10 2006-07-04 Generex Pharmaceuticals, Inc. Method for administering insulin to the buccal region
US6221378B1 (en) * 1998-02-10 2001-04-24 Generex Pharmaceuticals Incorporated Mixed micellar delivery system and method of preparation
EP1064382B1 (en) * 1998-03-17 2008-08-20 Genentech, Inc. Polypeptides homologous to vegf and bmp1
US6099859A (en) * 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US6358516B1 (en) * 1998-08-21 2002-03-19 Norris R. Harod One-step system for cleansing, conditioning, and treating the skin
US6500418B1 (en) * 1999-02-12 2002-12-31 The Washington University Stimulating neutrophil function to treat inflammatory bowel disease
EP1161261A1 (en) * 1999-03-11 2001-12-12 Human Genome Sciences, Inc. Apoptosis inducing molecule ii and methods of use
CA2396381A1 (en) * 2000-01-20 2001-07-26 Akira Yanagawa Nasally administrable cyclic peptide compositions
CA2337661A1 (en) * 2000-02-29 2001-08-29 Pfizer Products Inc. Stabilized granulocyte colony stimulating factor
US6432383B1 (en) * 2000-03-30 2002-08-13 Generex Pharmaceuticals Incorporated Method for administering insulin
FR2814074B1 (fr) * 2000-09-15 2003-03-07 Theramex Nouvelles compositions estro-progestatives topiques a effet systemique
DE60228294D1 (en) * 2001-06-05 2008-09-25 Ronald Aung-Din Topische migränetherapie
EP1284143A1 (en) * 2001-08-17 2003-02-19 Sifi S.p.A A process for the preparation of pharmaceutical formulations containing lactoferrin description
US20030083286A1 (en) * 2001-08-22 2003-05-01 Ching-Leou Teng Bioadhesive compositions and methods for enhanced intestinal drug absorption
US20030124196A1 (en) * 2001-08-22 2003-07-03 Susan Weinbach Pulsatile release compositions and methods for enhanced intestinal drug absorption
MXPA04005361A (es) * 2001-12-13 2004-09-27 Vital Health Sciences Pyt Ltd Transporte transdermico de compuestos.
NZ533062A (en) * 2001-12-19 2006-03-31 Alza Corp Formulation and dosage form for the controlled delivery of therapeutic agents
HUP0402451A3 (en) * 2001-12-19 2008-04-28 Alza Corp Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
US20030159702A1 (en) * 2002-01-21 2003-08-28 Lindell Katarina E.A. Formulation and use manufacture thereof
US20040037809A1 (en) * 2002-06-28 2004-02-26 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon beta
US20040248846A1 (en) * 2003-04-22 2004-12-09 Nastech Pharmaceutical Company Inc. Intranasal administration of triptans
US20040219229A1 (en) * 2003-04-30 2004-11-04 Tim Clarot Migraine relief composition and methods of using and forming same
US20040258663A1 (en) * 2003-05-08 2004-12-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon alpha
SI1644024T1 (sl) * 2003-06-06 2019-11-29 Univ Texas Protimikrobne raztopine za izpiranje
US20050031549A1 (en) * 2003-06-09 2005-02-10 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of growth hormone
HN2004000285A (es) * 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET

Also Published As

Publication number Publication date
US20020141970A1 (en) 2002-10-03
EP1372700A1 (en) 2004-01-02
EP1372700A4 (en) 2005-10-19
PT1372700E (pt) 2007-08-27
EP1372700B1 (en) 2007-05-16
US20070041938A1 (en) 2007-02-22
DK1372700T3 (da) 2007-09-24
US20080299071A1 (en) 2008-12-04
WO2002069999A1 (en) 2002-09-12
JP2004536038A (ja) 2004-12-02
JP2009161538A (ja) 2009-07-23
DE60220149T2 (de) 2007-12-13
DE60220149D1 (de) 2007-06-28
ATE362375T1 (de) 2007-06-15
ES2287296T3 (es) 2007-12-16

Similar Documents

Publication Publication Date Title
CY1107435T1 (el) Σταθερα υδατικα διαλυματα του παραγοντα διεγερσεως αποικιων κοκκιοκυτταρων μακροφαγων
HK1068626A1 (en) Chemical compounds
CY1106247T1 (el) Θειοφαινο- και θειαζολοσουλφοναμιδες ως αντινεοπλαστικοι παραγοντες
IS7037A (is) Notkun HMG hluta sem bólgueyðandi efni
PL361404A1 (en) Synergistic combinations comprising a renin inhibitor for cardiovascular diseases
BR0215405A (pt) Composições e processos de uso de collajolie
DE60201627D1 (de) Fluorelastomerzusammensetzungen
GB2390367B (en) Lipid profile modulation
MXPA03009314A (es) Composiciones que contienen imidazotriazinona para administracion nasal.
ATE450652T1 (de) Wässrige zusammensetzung
CO5580729A2 (es) Composiciones nutricionales que comprenden cistationina
MXPA03011128A (es) Composicion de sabor y fragancia.
MY128164A (en) Compounds
ATE232099T1 (de) Stabile xylometazolin- und oxymetazolinlösung
AU6210101A (en) Extendable housing consisting of assembly frames
GB0108903D0 (en) Novel crystalline forms of a factor Xa inhibitor
ATE294154T1 (de) Apfelsäureadditionssalze von terbinafin
DE60217424D1 (de) PWL logarithmischer Verstärker
MY128306A (en) Oct formulations
PL365687A1 (en) Novel trioxepan compounds
GB0113920D0 (en) Composition
DOP2002000329A (es) Composicion solida
AU2002306640A1 (en) Stable aqueous solutions of granulocyte macrophage colony-stimulating factor
AUPR551601A0 (en) Self stabilising table leg mechanism
ES1050833Y (es) Pieza para la union de tablas de entarimados de madera.